Clinically, the diagnosis, prognosis and treatment decision of PCa are primarily made on the basis of prostate-specific antigen (PSA) level, tumor stage and Gleason scoring [2, 3], often leading to a significant overdiagnosis, overtreatment or eventually the aggressiveness of PCa [4]. This evidence concerns the gene KLK3 and posterior cortical atrophy.